ClinicalTrials.gg
RecruitingNCT07702760IMPLEMENT HFUpdated Oct 13, 2026

Guideline Implementation and Quality of Care Evaluation in Patients With Heart Failure and Reduced Ejection Fraction (HFrEF)

An observational study in HFrEF - Heart Failure With Reduced Ejection Fraction and Guideline Adherence, sponsored by Jasper Brugts MD PhD. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Jasper Brugts MD PhD · Observational

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Oct 13, 2026Now RecruitingFirst site in Netherlands+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 313 studies in Heart Failure with a site in Netherlands — 57 open to participants now, 80 under way, 13 of them phase 3. Heart Failure · Netherlands.

Planned enrollment
13th of 76
1,500 · median 236
Started
2026
with 17 others
Observational
76 of 313
21 open now
Primary completion
2029-06
later than 64 of 79 live
Registered
310th of 313
by date

Among the 313 studies in Heart Failure with a site in Netherlands, this one is the 13th largest by planned enrollment of the 76 observational ones that give a count, is one of 18 that started in 2026, is one of 76 observational ones, reaches primary completion later than 64 of the 79 other live ones, and was the 310th registered.

Heart Failure

6,340 studies on the registry are indexed under Heart Failure; 1,397 are open to participants now.

Browse Heart Failure studies →

Open to participants now

57 of the 313 studies in Heart Failure with a site in Netherlands are open now. Recruiting first, the newest first:

51 more — sign in →

All 57 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 968 Heart Failure studies recruiting now, 691 (71%) set no upper age limit and 90 (9%) stop at 75 or younger; 64 take children under 18; 97 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 313 studies in Heart Failure with a site in Netherlands, or all of them as a file.
02

Study summary

The IMPLEMENT HF study is part of the national heart failure quality of care registry (evaluation of given health care). Within the HF registry, the investigators will investigate whether mirror information on the actual 4 pillars of guideline directed medical therapy (GDMT) in HFrEF patients will help to further improve the implementation of GDMT.

Data will be used from the national HF registry in the Netherlands. Two groups will be studied, one where the HCP receives the mirror information on GDMT and one where both the patient and the HCP receive the mirror information on GDMT. GDMT or the 4 pillars treatment is standard of care as recommended by the ESC HF guidelines, indicated for all HFrEF patients. The project is a quality of care registry and health care evaluation to optimize adherence to the HF guidelines.

Read the detailed description

The IMPLEMENT HF is a sequel study to the TITRATE HF study that has shown that the level of GDMT prescription in de novo HFrEF can be further improved. The investigators hypothesize that mirror information about actual levels of GDMT helps the physician and patient optimize GDMT as recommended in the guideline. The IMPLEMENT is a registry based study in 1500 with de novo HFrEF patients, in which mirror information on GDMT (4 pillars) prescription levels will be shown to the treating physician. In a second group (50%) both the physician and patient will receive the mirror information on the prescription of GDMT. For diversity, the investigators aim to include 50% elderly and 50% women in to the registry. The primary endpoint is the prescription level of GDMT. Secondary endpoints are the dosing levels of GDMT (% target dose) and incident clinical events.

03

Conditions studied

  • HFrEF - Heart Failure With Reduced Ejection Fraction
  • Guideline Adherence

Browse trials for

Keywords

  • guideline recommended drug therapy
04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with de novo / newly diagnosed heart failure with reduced ejection fraction

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Written
  2. Age ≥18 years
  3. Diagnosis of HFrEF according to ESC HF 2026 guidelines (EF \<50%)
  4. Participant is willing to participate for 1 years of follow-up for standard of care at the outpatient clinic of the participating hospital and the local investigator follows the patients for the time frame of 1 years on reported endpoints.

Exclusion criteria

Exclusion Criteria:

  1. An expected less than 1 year due to other comorbidities according to the treating physician
  2. A major CV event (e.g. disabling stroke, open heart surgery) within 3 months of enrollment, if likely to interfere with GDMT titration or regular follow-up.
  3. Advanced or Endstage Heart Failure stage in which advanced HF treatment with an LVAD or heart transplant is anticipated within 6 months after the baseline visit.

At enrollment the patient has an established diagnosis of heart failure with reduction .

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,500 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Guideline recommended drug therapy for HFrEF with mirror information to HCP

    Guideline recommended drug therapy for HFrEF with mirror information to HCP

  • Guideline recommended drug therapy for HFrEF with mirror information to HCP and patient

    Guideline recommended drug therapy for HFrEF with mirror information to HCP and patient.

06

What researchers measure

Primary outcomes

  1. The prescription level (%) of GDMT / 4 pillars in de novo HFrEF patients.

    The prescription level (%) of GDMT / 4 pillars in patients with de novo HFrEF at specific time moments durign 1 year (6 weeks, 3 Months , 6 Months, 12 Months)

    Time frame: 1 year of follow-up

Secondary outcomes

  1. The % of target dose of GDMT prescribed in de novo HFrEF patients

    The dosing level of a GDMT drug class as % of the guideline recommended dose during 1 year of follow-up.

    Time frame: 1 year (evaluated at time moments 6 weeks, 3 Months, 6 Months, 12 Months).

  2. Incident events

    The incidence of all-cause mortality and HF hospitalisations during 12 months of follow-up (and the individual components of the composite outcome).

    Time frame: 1 year of follow-up (12 months)

Other outcomes

  1. GDMT adherence in subgroups of age (elderly) and sex (men/women)

    GDMT adherence in subgroups of age (elderly) and sex (men/women)

    Time frame: 12 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — The project is part of the NHR HF registry and follow the protocols and rules of the NHR on IPD accordingly (including GDPR/AVG), when applicable.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Jun 2029, 34 months after the start.

Of 799 non-industry observational studies under Heart Failure, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 100. This study's planned 34 months is below that.

Counting every sponsor, half of 982 studies reached it within 41 months; a quarter within 23 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2026
First posted
Jul 14, 2026
StartActual
Jul 7, 2026
Primary completionEst.
Jun 1, 2029
CompletionEst.
Dec 1, 2029
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 13, 2026
Sites
1 site added — first site in Netherlands
Show site
  • Erasmus University Medical Centre · Rotterdam, Netherlands
Oct 13, 2026
Eligibility
1 inclusion criterion edited; 2 exclusion criteria edited
What changed in the criteria
Inclusion criteria
  • EditedDiagnosis of HFrEF according to ESC HF 2026 guidelines (EF <4050%)
Exclusion criteria
  • EditedA major CV event (e.g. disabling stroke, myocardial infarction, open heart surgery) within 3 months of enrollment, if likely to interfere with GDMT titration or regular follow-up.
  • EditedAt enrollment the patient has an established diagnosis of heart failure with reduction ejection fraction with an established EF below 40%.
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Not yet recruiting→Recruiting
    1 site added — first site in Netherlands
    Show site
    • Erasmus University Medical Centre · Rotterdam, Netherlands
    Eligibility 1 inclusion criterion edited; 2 exclusion criteria edited
    What changed in the criteria
    Inclusion criteria
    • EditedDiagnosis of HFrEF according to ESC HF 2026 guidelines (EF <4050%)
    Exclusion criteria
    • EditedA major CV event (e.g. disabling stroke, myocardial infarction, open heart surgery) within 3 months of enrollment, if likely to interfere with GDMT titration or regular follow-up.
    • EditedAt enrollment the patient has an established diagnosis of heart failure with reduction ejection fraction with an established EF below 40%.
    + 2 other changes: verification date and date precision

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07702760
Lead sponsor
Jasper Brugts MD PhD
Collaborators
Dutch Heart Foundation
Responsible party
Jasper Brugts MD PhD (Lead investigator of the CRO/Sponsor Erasmus MC, Department of Cardiology, Dr. Molewaterplein 40, Rotterdam, The Netherlands, Erasmus Medical Center) — Sponsor-investigator
First posted
Jul 14, 2026
Start date
Jul 7, 2026
Primary completion
Jun 1, 2029 (estimated)
Completion
Dec 1, 2029 (estimated)
Last update
Oct 13, 2026

Study contacts

Fleur Wildenbeest
Contact
f.wildenbeest@erasmusmc.nl
+31107040704
Rudolf de Boer, MD PhD
study chair · Erasmus Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion